Investigator:
Professor David Dunger, dp223@medschl.cam.ac.uk (UK Study coordinator)
Summary:
INNODIA is an international consortium with academic institutions, healthcare teams, scientific and industrial partners, and patient organisations which have joined forces to significantly improve the understanding of type 1 Diabetes and to pave the way to novel therapeutic options to prevent and cure this disease.
Professor Polly Bingley, polly.bingley@bristol.ac.uk
Beth Thorne, beth.thorne@bristol.ac.uk
TrialNet is an international network of leading academic institutions, physicians, scientists and healthcare teams dedicated to the prevention of type 1 diabetes.
To identify by offering risk screening and maintain a pool of people who may be eligible for entry into prevention trials, as these become available.
Proffessor John Todd
The purpose of this trial is to assess the safety, tolerability and optimal dose of Proleukin in children and adolescents with type 1 diabetes, through study of the effects on the immune system and metabolic parameters. Note this trial was originally called DILTY
Professor Colin Dayan, dayancm@cardiff.ac.uk
This is a double blind Phase 2 study to assess the safety and efficacy of Ustekinemab in children & adolescents aged 12 with new onset T1D. Participants will be given S/C Ustekinemab at weeks 0, 4, and 12 & every 8 weeks for 1 year. There will be 8 study visits over 1 year, 3 of which will be at home. Mixed meal tolerance tests will be performed at 0, 26 and 52 weeks. All participants will be offered CGMS using the Freestyle Librae system. An information video will be available at www.type1diabetesresearch.org.uk
Tracking of Risk for diabetic nephropathy and cardiovascular disease in young people with type 1 diabetes recruited to the AdDIT Study
Professor David Dunger, dbd25@cam.ac.uk
The AdDIT follow up study, is following up the AdDIT cohort to collect data to see if more relevant effects, such as those on direct manifestations of cardiovascular disease (CVD), renal and retinal disease, are most likely to become apparent in the longer term, during early adult life. Thus, long-term follow-up of the whole AdDIT cohort will allow the characterisation of rates of vascular complications during early adulthood reflecting a potential ‘metabolic memory’ of glycaemic and non-glycaemic exposures as well as treatment effects during pubertal years.